Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets

BACKGROUND: Axitinib is approved by the FDA for the treatment of advanced renal cell carcinoma (RCC) after failure of 1 previous systemic therapy and is distributed primarily through specialty pharmacies. Although the efficacy and safety of axitinib have been established in clinical trials, informat...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLean, Elizabeth, Cisar, Laura, Mehle, Kimberly, Eremina, Daria, Quigley, Jane M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397709/
https://www.ncbi.nlm.nih.gov/pubmed/27231799
http://dx.doi.org/10.18553/jmcp.2016.22.6.723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397709/
https://www.ncbi.nlm.nih.gov/pubmed/27231799
http://dx.doi.org/10.18553/jmcp.2016.22.6.723

Ejemplares similares